新型抗癌复方蟾山护金方干扰肺腺癌细胞增殖并诱导其凋亡的研究
|
摘要
目的:观察新型抗癌复方蟾山护金方含药血清对肺腺癌A549细胞增殖的影响,并探讨其能否诱导A549细胞凋亡。方法:将30只SD大鼠随机分成3组,分别为含药血清组、消癌平组、阴性血清组,每组10只,各组依次灌胃蟾山护金方煎剂、消癌平片水溶剂和生理盐水,制备含药血清,利用含药血清做A549细胞增殖抑制实验(MTT实验)、细胞凋亡实验和检测"死亡蛋白酶"caspase-3的表达变化。结果:通过MTT实验,发现蟾山护金方含药血清能够抑制A549细胞的增殖,且呈剂量相关性,与阴性血清组比较,差异有统计学意义(P <0. 05);与消癌平组比较,差异有统计学意义(P <0. 05)。通过流式细胞仪检测细胞凋亡,发现蟾山护金方含药血清中浓度组和高浓度组诱导A549细胞早期凋亡,与阴性血清组比较,差异有统计学意义(P <0. 05; P <0. 05)。通过Western-Blot实验发现A549细胞caspase-3激活上调。结论:新型抗癌复方蟾山护金方含药血清能抑制A549细胞的增殖并诱导其凋亡,且呈剂量正相关性。
Objective: To observe the effects of new anticancer prescription of Chanshan Hujin on the proliferation of lung adenocarcinoma A549 cells,and to investigate that whether it could induce the apoptosis of A519. Methods: A total of 30 SD rats were randomly divided into three groups of a serum containing drug group,a Xiao-Ai-Ping group and a normal saline group,with 10 rats in each group. Each group was intragastric administrated successively with the Decoction of Chan-Shan-Hu-Jin Prescription,XiaoAi-Ping water solvent and normal saline,to prepare the serum containing drug. A549 cell proliferation inhibition test( MTT test),apoptosis assay and detection the expression of"death protease"Caspase-3 was carried out with serum containing drug. Results:Through the cell proliferation inhibition test( MTT test),it was found that the group of Chan-Shan-Hu-Jin Prescription could inhibit the proliferation of A549 cells,and had positive correlation with dose. Compared with the negative group,the difference was significant( P < 0. 05). The difference was significant when compared with the Xiao-Ai-Ping group( P < 0. 05). The apoptotic detection was carried out by flow cytometry. It was found that the early apoptosis rate after the medium concentration treatment group and high concentration treatment group,and it had significant difference when compared with the negative group( P < 0. 05,P < 0. 05). Western-Blot test showed that the activation of"death protease"caspase-3 was up-regulated. Conclusion: The serum containing drug of Chan-Shan-Hu-Jin Prescription can inhibit the proliferation and induce the apoptosis of A549 cell,and has positive correlation with dose.
Objective: To observe the effects of new anticancer prescription of Chanshan Hujin on the proliferation of lung adenocarcinoma A549 cells,and to investigate that whether it could induce the apoptosis of A519. Methods: A total of 30 SD rats were randomly divided into three groups of a serum containing drug group,a Xiao-Ai-Ping group and a normal saline group,with 10 rats in each group. Each group was intragastric administrated successively with the Decoction of Chan-Shan-Hu-Jin Prescription,XiaoAi-Ping water solvent and normal saline,to prepare the serum containing drug. A549 cell proliferation inhibition test( MTT test),apoptosis assay and detection the expression of"death protease"Caspase-3 was carried out with serum containing drug. Results:Through the cell proliferation inhibition test( MTT test),it was found that the group of Chan-Shan-Hu-Jin Prescription could inhibit the proliferation of A549 cells,and had positive correlation with dose. Compared with the negative group,the difference was significant( P < 0. 05). The difference was significant when compared with the Xiao-Ai-Ping group( P < 0. 05). The apoptotic detection was carried out by flow cytometry. It was found that the early apoptosis rate after the medium concentration treatment group and high concentration treatment group,and it had significant difference when compared with the negative group( P < 0. 05,P < 0. 05). Western-Blot test showed that the activation of"death protease"caspase-3 was up-regulated. Conclusion: The serum containing drug of Chan-Shan-Hu-Jin Prescription can inhibit the proliferation and induce the apoptosis of A549 cell,and has positive correlation with dose.
引文
[1]Siegel R,Naishadham D,Jemal A.Cancer statistics for Hispanics/Latinos,2012[J].CA Cancer J Clin,2012,62(5):283-298.
[2]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CACancer J Clin,2011,61(2):69-90.
[3]蔡亮,张凌华,杨子杰,等.嵌合抗原受体T细胞(CAR-T)免疫疗法:绝处逢生的利剑[J].自然杂志,2016,38(3):228-231.
[4]张萱,张培彤.近20年来治疗肺癌中草药研究概况[J].中国肿瘤,2002,11(6):330-333.
[5]冯青,郑红英.复方苦参注射液联合GP方案治疗不同分期NSCLC患者的临床评价[J].世界中医药,2018,13(5):1164-1167,1171.
[6]贾彦焘,于建春,张丽丽,等.肺一丸对LA-795肺腺癌细胞增殖的影响[J].河北中医,2009,31(3):444-446.
[7]施璐,艾中柱,张德忠,等.参七抗癌散抗肿瘤及其镇痛作用[J].武汉大学学报:医学版,2016,37(3):411-413,484.
[8]周建军.扶正抗癌散在肺癌化疗中的增效与减毒的临床观察[J].中医临床研究,2017,9(11):35-36.
[9]滕树财.青龙抗癌散治疗恶性肿瘤87例临床报告[J].蛇志,2009,21(3):222-222,255.
[10]戚敏,刘红,胡香杰,等.化瘀解毒抗癌散抗肿瘤作用的实验研究[J].河南肿瘤学杂志,2002,15(4):266-268.
[11]邓鹏.华蟾素注射液联合PC化疗方案对非小细胞肺癌患者血清CA125、CEA水平变化的影响[J].北方药学,2018,15(5):108-109.
[12]徐聪,吴其标.华蟾素治疗非小细胞肺癌的临床研究进展[J].中医药导报,2017,23(17):100-103.
[13]邓日强,杨印楼,张宏华,等.蚤休薯蓣皂苷联合顺铂治疗肺腺癌小鼠的疗效及其作用机制研究[J].实用心脑肺血管病杂志,2016,24(7):56-60.上接第页
[14]Jung EB,Trinh TA,Lee TK,et al.Curcuzedoalide contributes to the cytotoxicity of Curcuma zedoaria rhizomes against human gastric cancer AGS cells through induction of apoptosis[J].J Ethnopharmacol,2018,213:48-55.
[15]杨长福,李亚东,牛建昭,等.莪术油对肺癌A549细胞周期及组织蛋白酶K表达的影响[J].中国实验方剂学杂志,2010,16(8):113-116.
[16]范丽娜,张鹏鹏.运用联合方组治疗肺癌体会[J].山西职工医学院学报,2017,27(6):55-56.
[17]熊婵,何成诗,王俭,等.百合固金汤治疗肺癌临床特色[J].亚太传统医药,2016,12(17):59-60.
[18]王红兵,蒲志忠,邓彬,等.青蒿鳖甲汤对肺癌骨转移患者细胞因子的影响[J].世界中医药,2018,13(3):665-668.
[19]Liu J,Lin HS,Hou W,et al.Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer:Amulticenter,prospective,cohort study[J].Chin J Integr Med,2017,23(10):733-739.
[20]Tseng CY,Lin CH,Wu LY,et al.Potential Combinational AntiCancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin[J].PLo S One,2016,11(5):e0155469.(收稿责任编辑:王明)
[2]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CACancer J Clin,2011,61(2):69-90.
[3]蔡亮,张凌华,杨子杰,等.嵌合抗原受体T细胞(CAR-T)免疫疗法:绝处逢生的利剑[J].自然杂志,2016,38(3):228-231.
[4]张萱,张培彤.近20年来治疗肺癌中草药研究概况[J].中国肿瘤,2002,11(6):330-333.
[5]冯青,郑红英.复方苦参注射液联合GP方案治疗不同分期NSCLC患者的临床评价[J].世界中医药,2018,13(5):1164-1167,1171.
[6]贾彦焘,于建春,张丽丽,等.肺一丸对LA-795肺腺癌细胞增殖的影响[J].河北中医,2009,31(3):444-446.
[7]施璐,艾中柱,张德忠,等.参七抗癌散抗肿瘤及其镇痛作用[J].武汉大学学报:医学版,2016,37(3):411-413,484.
[8]周建军.扶正抗癌散在肺癌化疗中的增效与减毒的临床观察[J].中医临床研究,2017,9(11):35-36.
[9]滕树财.青龙抗癌散治疗恶性肿瘤87例临床报告[J].蛇志,2009,21(3):222-222,255.
[10]戚敏,刘红,胡香杰,等.化瘀解毒抗癌散抗肿瘤作用的实验研究[J].河南肿瘤学杂志,2002,15(4):266-268.
[11]邓鹏.华蟾素注射液联合PC化疗方案对非小细胞肺癌患者血清CA125、CEA水平变化的影响[J].北方药学,2018,15(5):108-109.
[12]徐聪,吴其标.华蟾素治疗非小细胞肺癌的临床研究进展[J].中医药导报,2017,23(17):100-103.
[13]邓日强,杨印楼,张宏华,等.蚤休薯蓣皂苷联合顺铂治疗肺腺癌小鼠的疗效及其作用机制研究[J].实用心脑肺血管病杂志,2016,24(7):56-60.上接第页
[14]Jung EB,Trinh TA,Lee TK,et al.Curcuzedoalide contributes to the cytotoxicity of Curcuma zedoaria rhizomes against human gastric cancer AGS cells through induction of apoptosis[J].J Ethnopharmacol,2018,213:48-55.
[15]杨长福,李亚东,牛建昭,等.莪术油对肺癌A549细胞周期及组织蛋白酶K表达的影响[J].中国实验方剂学杂志,2010,16(8):113-116.
[16]范丽娜,张鹏鹏.运用联合方组治疗肺癌体会[J].山西职工医学院学报,2017,27(6):55-56.
[17]熊婵,何成诗,王俭,等.百合固金汤治疗肺癌临床特色[J].亚太传统医药,2016,12(17):59-60.
[18]王红兵,蒲志忠,邓彬,等.青蒿鳖甲汤对肺癌骨转移患者细胞因子的影响[J].世界中医药,2018,13(3):665-668.
[19]Liu J,Lin HS,Hou W,et al.Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer:Amulticenter,prospective,cohort study[J].Chin J Integr Med,2017,23(10):733-739.
[20]Tseng CY,Lin CH,Wu LY,et al.Potential Combinational AntiCancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin[J].PLo S One,2016,11(5):e0155469.(收稿责任编辑:王明)